Clinical diagnosis and treatment of superficial bladder carcinoma [Klinische diagnostik und therapie des oberflächlichen harnblasenkarzinoms]

[21] Mian C., Pycha A., Wiener H., Haitel A., Lodde M., Marberger M., Immunocyt: A new tool for detecting transitional cell cancer of the urinary tract, J Urol, 161, 5, pp. 1486-1489, (1999)

[22] Mulders P.F., Hoekstra W.J., Heybroek R.P., Schapers E.R., Verbeek A.L., Oosterhof G.O., Debruyne F.M., Prognosis and treatment of T1G3 bladder tumours. A prognostic factor analysis of 121 patients. Dutch South Eastern Bladder Cancer Study Group, Eur J Cancer, 30 A, pp. 914-917, (1994)

[23] Oosterlinck W., Kurth K.-H., Schroder F., Bultinck J., Hammond B., Sylvester R., A prospective European Organization for Research and Treatment of Cancer genitourinary group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder, J Urol, 149, pp. 749-752, (1993)

[24] Shelley M.D., Court J.B., Kynaston H., Wilt T.J., Fish R.G., Mason M., Intravesical Bacillus Calmette-Guérin in Ta and T1 Bladder Cancer (Cochrane Review), The Cochrane Library, 4, pp. 1-14, (2000)

[25] Tolley D.A., Parmar M.K.B., Grigor K.M., Lallemand G., The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: A further report with 7 years of follow-up, J Urol, 155, pp. 1233-1238, (1996)

[26] Voutsa N.G., Melamed M.R., Cytology of in Situ Carcinoma of the Human Urinary Bladder, C16, pp. 1307-1316, (1963)

[27] Zein T., Wajsman Z., Englander L.S., Gamarra M., Lopez C., Huben R.P., Pontes J.E., Evaluation of bladder washings and urine cytology in the diagnosis of bladder cancer and its correlation with selected biopsies of the bladder mucosa, J Urol, 132, pp. 670-671, (1984)

[21] Mian C., Pycha A., Wiener H., Haitel A., Lodde M., Marberger M., Immunocyt: A new tool for detecting transitional cell cancer of the urinary tract, J Urol, 161, 5, pp. 1486-1489, (1999)

[22] Mulders P.F., Hoekstra W.J., Heybroek R.P., Schapers E.R., Verbeek A.L., Oosterhof G.O., Debruyne F.M., Prognosis and treatment of T1G3 bladder tumours. A prognostic factor analysis of 121 patients. Dutch South Eastern Bladder Cancer Study Group, Eur J Cancer, 30 A, pp. 914-917, (1994)

[23] Oosterlinck W., Kurth K.-H., Schroder F., Bultinck J., Hammond B., Sylvester R., A prospective European Organization for Research and Treatment of Cancer genitourinary group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder, J Urol, 149, pp. 749-752, (1993)

[24] Shelley M.D., Court J.B., Kynaston H., Wilt T.J., Fish R.G., Mason M., Intravesical Bacillus Calmette-Guérin in Ta and T1 Bladder Cancer (Cochrane Review), The Cochrane Library, 4, pp. 1-14, (2000)

[25] Tolley D.A., Parmar M.K.B., Grigor K.M., Lallemand G., The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: A further report with 7 years of follow-up, J Urol, 155, pp. 1233-1238, (1996)

[26] Voutsa N.G., Melamed M.R., Cytology of in Situ Carcinoma of the Human Urinary Bladder, C16, pp. 1307-1316, (1963)

[27] Zein T., Wajsman Z., Englander L.S., Gamarra M., Lopez C., Huben R.P., Pontes J.E., Evaluation of bladder washings and urine cytology in the diagnosis of bladder cancer and its correlation with selected biopsies of the bladder mucosa, J Urol, 132, pp. 670-671, (1984)